

Amira Guirguis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1559399/publications.pdf>

Version: 2024-02-01

46
papers

1,209
citations

430874

18
h-index

414414

32
g-index

49
all docs

49
docs citations

49
times ranked

1056
citing authors

#	ARTICLE	IF	CITATIONS
1	An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 270-277.	2.1	105
2	COVID-19: The Hidden Impact on Mental Health and Drug Addiction. <i>Frontiers in Psychiatry</i> , 2020, 11, 767.	2.6	101
3	The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. <i>Frontiers in Psychiatry</i> , 2017, 8, 240.	2.6	75
4	The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. <i>Brain Sciences</i> , 2021, 11, 355.	2.3	66
5	Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems. <i>Frontiers in Pharmacology</i> , 2019, 10, 46.	3.5	58
6	Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. <i>Brain Sciences</i> , 2018, 8, 73.	2.3	56
7	Identification of new psychoactive substances (NPS) using handheld Raman spectroscopy employing both 785 and 1064 nm laser sources. <i>Forensic Science International</i> , 2017, 273, 113-123.	2.2	51
8	"New/Designer Benzodiazepines": An Analysis of the Literature and Psychonauts' Trip Reports. <i>Current Neuropharmacology</i> , 2020, 18, 809-837.	2.9	51
9	The clinical challenges of synthetic cathinones. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 410-419.	2.4	50
10	Survey of knowledge of legal highs (novel psychoactive substances) amongst London pharmacists. <i>Drugs and Alcohol Today</i> , 2015, 15, 93-99.	0.7	49
11	Intended and unintended use of cathinone mixtures. <i>Human Psychopharmacology</i> , 2017, 32, e2598.	1.5	46
12	Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants. <i>Frontiers in Psychiatry</i> , 2021, 12, 657397.	2.6	40
13	New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. <i>Experimental Neurology</i> , 2021, 339, 113638.	4.1	29
14	The Psychonauts' World of Cognitive Enhancers. <i>Frontiers in Psychiatry</i> , 2020, 11, 546796.	2.6	24
15	Novel Opioids: Systematic Web Crawling Within the e-Psychonauts' Scenario. <i>Frontiers in Neuroscience</i> , 2020, 14, 149.	2.8	24
16	Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. <i>Frontiers in Psychiatry</i> , 2020, 11, 632405.	2.6	24
17	Detection of newly emerging psychoactive substances using Raman spectroscopy and chemometrics. <i>RSC Advances</i> , 2018, 8, 31924-31933.	3.6	21
18	Beyond the "purple drank": Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports. <i>Journal of Psychopharmacology</i> , 2021, 35, 681-692.	4.0	21

#	ARTICLE	IF	CITATIONS
19	Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK. <i>Brain Sciences</i> , 2018, 8, 58.	2.3	20
20	Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. <i>Brain Sciences</i> , 2020, 10, 105.	2.3	20
21	New psychoactive substances: a public health issue. <i>International Journal of Pharmacy Practice</i> , 2017, 25, 323-325.	0.6	18
22	Piloting the UK's First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2020, 10, 121.	2.1	18
23	NPS detection in prison: A systematic literature review of use, drug form, and analytical approaches. <i>Drug Testing and Analysis</i> , 2022, 14, 1350-1367.	2.6	17
24	Benefits and Harms of "Smart Drugs" (Nootropics) in Healthy Individuals. <i>Drugs</i> , 2022, 82, 633-647.	10.9	17
25	The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1253-1264.	2.8	16
26	New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 580.	2.0	16
27	The e-Psychonauts' "Spiced" World; Assessment of the Synthetic Cannabinoids' Information Available Online. <i>Current Neuropharmacology</i> , 2020, 18, 966-1051.	2.9	16
28	The e-psychonaut drugs' psychopharmacology. <i>Current Opinion in Pharmacology</i> , 2021, 57, 165-174.	3.5	14
29	Drowning in diversity? A systematic way of clustering and selecting a representative set of new psychoactive substances. <i>RSC Advances</i> , 2017, 7, 53181-53191.	3.6	13
30	Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise. <i>European Neuropsychopharmacology</i> , 2021, 49, 69-92.	0.7	13
31	COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. <i>Brain Sciences</i> , 2021, 11, 907.	2.3	11
32	Psychedelic Fauna for Psychonaut Hunters: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 153.	2.6	10
33	Misuse of Anticholinergic Medications: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 355.	3.2	10
34	Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). <i>Pharmaceuticals</i> , 2022, 15, 675.	3.8	10
35	Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances. <i>Brain Sciences</i> , 2020, 10, 142.	2.3	9
36	What About Drug Checking? Systematic Review and Netnographic Analysis of Social Media. <i>Current Neuropharmacology</i> , 2020, 18, 906-917.	2.9	9

#	ARTICLE	IF	CITATIONS
37	A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. <i>Pharmaceuticals</i> , 2022, 15, 565.	3.8	9
38	Method development for the determination of elements in <i>Hypericum perforatum</i> L. (St John's) Tj ETQq0 0 0 rgBT /Overlock 10 T microwave digestion. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 71, 38-45.	2.4	7
39	New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. <i>Current Addiction Reports</i> , 2019, 6, 140-152.	3.4	7
40	Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: A quantitative study. <i>PLoS ONE</i> , 2022, 17, e0262704.	2.5	7
41	The Psychonauts™ Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity. <i>Pharmaceuticals</i> , 2021, 14, 720.	3.8	6
42	Substance-Use Disorders and Violence. <i>Comprehensive Approach To Psychiatry</i> , 2020, , 95-114.	1.0	6
43	How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 452-481.	2.4	5
44	Designer Benzodiazepines™ Activity on Opioid Receptors: A Docking Study. <i>Current Pharmaceutical Design</i> , 2022, 28, 2639-2652.	1.9	3
45	Knowledge and Use of Over-the-counter Drugs in Italy: An Exploratory Survey-based Study in the General Population. <i>Current Neuropharmacology</i> , 2023, 21, 133-141.	2.9	3
46	<i>In silico</i> studies on recreational drugs: 3D quantitative structure activity relationship prediction of classified and <i>de novo</i> designer benzodiazepines. <i>Chemical Biology and Drug Design</i> , 2023, 101, 40-51.	3.2	3